The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
List view / Grid view
Filter the results
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
Vernalis Research is based at Granta Park in Cambridge, UK and specialises in the development and application of fragment- and structure-based drug discovery methods. Nikki Withers met with Vernalis’ Research Director, James Murray, to discuss the company’s innovative approach to target discovery and how they sustain symbiotic collaborations to progress…
Steven van Helden, Chief Technology Officer at Pivot Park Screening Centre (PPSC), relies on efficient microplate readers for effective hit discovery.
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
Researchers have discovered a particular protein that is required for enterovirus replication and survival, presenting a therapeutic target.
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
A potential treatment for polycystic kidney disease has shown positive results in animal testing.
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
Researchers have developed a new cocktail of drugs that shrink pancreatic tumours in mice by blocking pathways that cancer cells use.
An algorithm has been developed which can predict the outcomes of complex chemical reactions with over 90 percent accuracy which can be applied to drug development.
A new study has demonstrated the possibility of treating antibiotic-resistant Pseudomonas aeruginosa which causes sepsis in burn patients.
A team from MIT sequenced bacteria samples from the digestive system which can be accessed by researchers to use in the development of treatments.